Investigating the plasma lipid lowering effects of the human milk oligosaccharide 3SL

Navn på bevillingshaver

Kaare Villum Grunddal


DKK 709,242




Internationalisation Fellowships


Recently, one specific natural compound found in humans was reported to lower plasma triglycerides and cholesterol concentrations by up to 50% in hyperlipidimic mice, making it one of the most effective triglyceride and cholesterol lowering compounds known. However, the underlying molecular mechanisms responsible for this effect remains elusive and determining these is the aim of my project.


Cardiovascular disease (CVD) accounts for a third of all deaths globally and is therefore the leading cause of death for both women and men. Although the available treatment regimens reduce the risk for CVD-related co-morbidity and death to some extent, the fact that CVD is still the leading cause of death clearly highlights that more effective therapeutic strategies are urgently needed. Recently, it has become clear that increased circulating triglyceride levels are a significant risk factor for CVD and compounds that would lower circulating triglyceride levels is thus needed. The significance of current project lies in the therapeutic potential of this specific natural compound, which may be used in the prevention of fatal CVD events.


This project will primarily be conducted at the University of California, San Diego, School of Medicine, Division of Endocrinology and Metabolism. This is the ideal place to carry out this study, since they have the required experimental platforms and the knowledge to carry out studies to determine the physiological effects of this specific compound. These studies includes, but are not limited to, RNAseq, lipoprotein and lipidomic analyses. To supplement these methods, I will apply my expertise on gut physiology and metabolism using a unique combination of state-of-the-art histological methods, including transcriptomics.

Tilbage til oversigtssiden